Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23253422 | 0.79 | HSP90AA1 (0.41) | MAPTHSP90AA1GPR55 | |
| SCHEMBL3905334 | 0.76 | ALDH1A1 (0.32) | MAPTALDH1A1LMNAGAAATM | |
| SCHEMBL4110166 | 0.75 | — | — | |
| SCHEMBL53472 | 0.75 | — | — | |
| SCHEMBL5773491 | 0.73 | — | — | |
| SCHEMBL80876 | 0.72 | HSP90AA1 (0.44) | MAPTHSP90AA1GPR55 | |
| Silver SCHEMBL30466753 | 0.72 | — | — | |
| SCHEMBL29010312 | 0.72 | — | — | |
| SCHEMBL11003807 | 0.71 | — | — | |
| SCHEMBL6331108 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546452-B2 | S1P3 receptor antagonist | TOA EIYO LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1450811-B1 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARM INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | BAYER HEALTHCARE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1465872-A1 | 4-SULFIDE/SULFOXIDE/SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | Bayer Pharmaceuticals Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| CN-1514828-A | Pyrazole derivatives for treating HIV | — | 2004-07-21 | — | — | CN | disclosed |
| WO-2003057674-A1 | 4-SULFIDE / SULFOXIDE / SULFONYL-1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | MAPT 2220/4885HSP90AA1 4330/4885GPR55 2285/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | MAPT 2163/4885HSP90AA1 4125/4885GPR55 2358/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | MAPT 1474/4885HSP90AA1 3871/4885GPR55 2382/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | MAPT 2150/4885HSP90AA1 3634/4885GPR55 2698/4885 |
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | HTR2C, HTR2A, HTR2B | MAPT 4451/4885HSP90AA1 2093/4885GPR55 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.